Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients

Leukemia and Lymphoma

Volumn 33, Issue 1-2, 1999, Pages 77-82

  Aviram, A ^a   Blickstein, D ^a   Stark, P ^a   Luboshitz, J ^a   Bairey, O ^a   Prokocimer, M ^a   Shaklai, M ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

BCR ABL; Essential thrombocythemia; Myeloproliferative disorders; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN;

ADULT; AGED; BONE MARROW BIOPSY; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTHEMIA;

EID: 0033005125     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909093727     Document Type: Review

References (32)

1. Fialkow, P.J., Faguet, G.B., Jacobson, R.J., Raidya, K. and Murphy, S. (1981). Evidance that essential thrombocythaemia is a clonal disorder with origin in multipotent stem cell. Blood, 58, 916-919.
2. Groffen, J., Stephenson J.R., Heisterkamp, N., De Klein, A., Bartram, C.R. and Grosveld, G. (1984). Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell, 36, 93-99.
3. Shtivelman E., Lifshitz, B. Gale R.P. and Canaani, E. (1985). Fused transcript of abl and ber genes in chronic myelogenous leukemia. Nature, 315, 550-555.
4. Ben-Neriah, Y., Daley, G.O., Mes-Masson, A.M., Witte, O.N. and Baltimore, D. (1986). The chronic myelogenous leukemia specific p210 protein is the product of the BCR/ABL hybrid gene. Science, 233, 212-214.
5. De Klein, A. (1987). Oncogene activation by chromosomal rearrangement in chronic myeloid leukemia. Mutat. Res., 186, 161-172.
6. Melo, J.V. (1996). The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88, 2375-2384.
7. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S. and Jones R.J. (1994). Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 83, 2038-2044.
8. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R. and Cotter, T.G. (1994). BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83, 1179-1187.
9. Saglio, G., Guerrasio, A., Rosso C., Zaccaria, A., Tassinari, A., Serra, A., Rege-Cambrin, G., Mazza, U. and Gavosto, F. (1990). New type of BCR-ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood, 76, 1819-1824.
10. Wada, H., Mizutani, S., Nishimura, J., Usuki, Y., Kohsakj, M., Komai, M., Keneko, H., Sakamoto, S., Delia, D., Kanamaru, A. and Kakishita, E. (1995). Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR-ABL fusion protein. Cancer Res., 55, 3192-3196.
11. Pane, F., Frigeri, F., Sinodna, M., Luciano, L., Ferrara, F., Cimino, R., Meloni G., Saglio, G., Salvatore, F. and Rotoli, B. (1996). Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR-ABL with c3/a2 junction). Blood, 88, 2410-2414.
12. Yamagata, T., Mitani, K., Kanda, Y., Yazaki, Y. and Hirai, H. (1996). Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous lekemia. Brit. J. Haemat., 94, 370-372.
13. Melo, J.V., Myint, H., Galton, D.A.G. and Goldman, J.M. (1994). P190 BCR-ABL chronic myeloid leukemia: the missing like with chronic myelomonocytic leukemia. Leukemia, 8, 208-211.
14. El-Kassar, N., Hetet. G., Brie're, J. and Grandchamp, B. (1997). Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets. Blood, 89, 128-134.
15. Douer, D., Fabian, I. and Cline, M.J. (1983). Circulating pluripotent haematopoietic cells in patients with myeloproliferative disorders. Br. J. Haematol., 54, 373-381.
16. Goldman, J.M., Shiota, F. Th'ng, K.M. and Orchard, K.H. (1980). Circulating granulocyte and erythroid progenitor cells in chronic granulocytic leukemia. Br. J. Haematol., 46, 7-13.
17. Croziat, H., Amato, D., McLeod, D.L., Eskinazi, D. and Axelrad, A. (1983). Differences among myeloproliferative disorders in the behaviour of their restricted progenitor cells in culture. Blood, 62, 578-584.
18. Fauser, A.A. and Messner, H.A. (1981). Pluripotent haematopoietic progenitors (CFU-GEMM) in polycythaemia vera: analysis of erythropoietin requirement and proliterative activity. Blood, 58, 1224-1227.
19. Kornberg, A., Fibach, E., Treves, A., Goldfarb, A. and Rachmilewitz, E.A. (1982). Circulating erythroid progenitors in patients with spent polycythaemia vera and myelofibrosis with myeloid metaplasia. Br.J. Haemat., 52, 573-578.
20. Adams, J.A., Barret, A.J. and McCarty, B.D.M. (1988). Primary polycythaemia, essential thrombocythaemia and myelofibrosis - three facets of a single disease process? Acta Haemat., 79, 33-37.
21. Morris, C.M., Fitzgerald, P.H., Holling, P.E., Archer, S.A., Rosman, I. and Beard, M.E. (1988). Essential thrombocythhemia and Philadelphia chromosome. Brit. J. Haemat., 70, 13-19.
22. Morris, CM., Heisterkamp, N., Groffen, J. and Fitzgerald, PH. (1991). Entire ABL gene is joined with 5′-BCR in some patients with philadelphia-positive leukemia. Blood, 78, 1078-1084.
23. Stoll, D.B., Peterson, P., Exton, R., Laszlo, J., Pisciotta, A.V., Ellis, J.T., White, P., Vaidya, K., Bozdech M. and Murphy, S. (1988). Clinical presentation and natural history of patients with essential thromobocythemia and the Philadelphia chromosome. Am. J. Hematol., 27, 77-83.
24. Matriat, P., Ifrah, N., Rassol, F., Morgan, G., Giles, F., Gow, J. and Goldman, J.M. (1989). Molecular analysis of philadelphia positive essential thrombocythemia. Leukemia, 3, 563-565.
25. Michiels, J.J. and Juvonen, E. (1997). Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the thrombocythemia vera study group. Sem. Thrombosis and Hemostasis, 23, 339-347.
26. Marasca, R., Luppi, M., Zucchini, P., Longo, G., Torelli, G., and Emillia, G. (1998). Might essential thrombocythemia carry Ph anomaly?. Blood, 91, 3084-3089.
27. Goldman J.M. (1997). Chronic myeloid leukemia. Curr. Opin. Hematol., 4, 277-285.
28. Vickers, M. (1996). Estimation of the number of mutations necessary to cause chronic myeloid leukemia from epidemiological data. Brit. J. Haematol., 94, 1-4.
29. Blickstein, D., Aviram, A., Luboshitz, J., Prokocimer, M., Stark, P., Bairey, O., Sulkes, J. and Shaklai, M. (1997). BCR-ABL transcripts in bone marrow aspirates of philadelphia-negative essential thrombocythemia patients: Clinical presentation. Blood, 90, 2768-2771.
30. Cervantes, F., Urbano Ispizua, A., Villamor, N., Feliu, E., Milla Montserrat, E. and Rozman, C. (1993). Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and terminating into megakaryoblastic blast crisis/: Report of two cases with molecular studies. Leukemia, 7, 327-330.
31. Inokuchi, K., Inoue, T., Tojo, A., Futaki, M., Miyake, K., Yamada, T., Tanabe, Y., Ohki, I., Dan, K., Ozawa, K., Asano, S. and Nomura, T. (1991). A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood, 78, 3125-3127.
32. Ardern, JC., Speak, J., Hyde, K., Hunt, LP., Lawson, R., Gorst, DW., Geary, CG. and Lucas GS. (1993). Molecular analysis in chronic granulocytic leukemia: location of breakpoints within M-bcr and relationship with presentation platelet count. Clin. Lab. Haematol., 15, 253-258.